elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Octreotide
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Octreotide
RIS
0.001
(Research Intensity Score)
Papers
116
Top papers
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 · 339 citations
[ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.
2024 · 45 citations
Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
2019 · 417 citations
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
2025 · 17 citations
Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
2021 · 85 citations
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
2025 · 5 citations
Gastroenteropancreatic Neuroendocrine Tumors
2025 · 4 citations
Congenital Chylothorax of the Newborn: A Systematic Analysis of Published Cases between 1990 and 2018
2021 · 72 citations
Clinical outcomes of medical therapy, EUS-guided ethanol ablation, and surgical resection in insulinoma: a clinical epidemiology study
2026
Newest papers
Clinical outcomes of medical therapy, EUS-guided ethanol ablation, and surgical resection in insulinoma: a clinical epidemiology study
2026
Outcomes of peptide receptor radionuclide therapy after progression following hepatic cytoreductive operation for neuroendocrine tumors
2026
Mo1830 A MACHINE LEARNING MODEL TO PREDICT RESPONSE TO RADIOLIGAND THERAPY IN PATIENTS WITH ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS PROGRESSIVE AFTER SOMATOSTATIN ANALOGS
2026
Mo1830 A MACHINE LEARNING MODEL TO PREDICT RESPONSE TO RADIOLIGAND THERAPY IN PATIENTS WITH ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS PROGRESSIVE AFTER SOMATOSTATIN ANALOGS
2026
Chylothorax after pediatric cardiac surgery: pathophysiology, diagnosis, and evolving management strategies
2026
An Overview of Radiopharmaceutical Therapy
2026
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
2025 · 17 citations
177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial
2025 · 5 citations
Gastroenteropancreatic Neuroendocrine Tumors
2025 · 4 citations
Browse all papers →
Octreotide's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Octreotide's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link